Clinical trials: Localized Pancreas Cancer
Pancreatic Cancer
A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .
In this study, a new chemotherapeutic agent, panitumumab, will be tested in combination with another chemotherapeutic drug, capecitabine, along with external radiotherapy, to find out whether this combination is effective and…
- Trial name
- PMABIIS (NCT01130701)
- Testing
- Neoadjuvant capecitabine, panitumumab and radiation
- Where
- United States
- Sponsor
- University of Massachusetts, Worcester
Pancreatic Cancer
Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00335543
- Testing
- cisplatin, gemcitabine hydrochloride, adjuvant therapy
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 254 people
- Sponsor
- Interdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft
Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.
- Conditions
- Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07645651
- Testing
- Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Washington
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma
- Trial name
- NCT00049023
- Testing
- 90Y-DOTA-tyr3-OCTREOTIDE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- O'Dorisio, M S